We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Aids Early Detection of Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 09 Mar 2015
A blood test that measures the levels of a certain protein can be used in conjunction with clinical assessments to assist with the diagnosis of rheumatoid arthritis is now available in North America.

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that primarily affects joints and it may result in deformed and painful joints, which can lead to loss of function. More...
The disease may also have signs and symptoms in organs other than joints.

The JOINTstat test (Augurex Life Science; Vancouver, BC, Canada) measures 14-3-3η (eta), a protein involved in joint damage that leads to debilitation in patients with RA, a disease that affects one out of every 100 Canadians. High levels of 14-3-3η protein indicate that the patient should be referred to a rheumatologist. JOINTstat has been evaluated in clinical studies in over 3,000 patients and has been available in the USA since late 2013.

Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signaling pathways that lead to the upregulation of inflammation and joint damage factors involved in RA pathogenesis. A quantitative enzyme-linked immunosorbent assay is used to assess 14-3-3η protein levels. Studies have shown that when the test is positive, greater than 0.19 ng/mL, it provides a 5 to 50 times greater likelihood of having RA versus non-RA. At high levels of greater than 80 ng/mL is an indicator of RA that will lead to more joint damage over three years and at lower levels of less than 0.4 ng/mL or negative in RA diagnosed patients indicates a higher likelihood of response to RA therapy.

Walter Maksymowych, MD, FRCPC, a professor in the department of medicine, division of rheumatology at the University of Alberta (Edmonton, AB, Canada) said, “When diagnosed early, rheumatoid arthritis can be better managed with drug therapies, resulting in better outcomes by limiting disease progression. Current diagnostic tests are limited in their ability to catch the disease early. With the availability of JOINTstat in Canada, physicians now have the opportunity to treat rheumatoid arthritis early, prior to the onset of significant joint damage. This represents an important milestone towards the goal of personalized medicine.” The study was presented at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting held February 4–7, 2015, in Québec City (QC, Canada).

Related Links:

Augurex Life Science
University of Alberta



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.